Please login to the form below

Not currently logged in
Email:
Password:

loxapine

This page shows the latest loxapine news and features for those working in and with pharma, biotech and healthcare.

Teva launches first inhaled antipsychotic in US

Teva launches first inhaled antipsychotic in US

Adasuve (loxapine) was originally developed by US company Alexza Pharmaceuticals and becomes the first and only inhaled antipsychotic drug for this indication in the US market. ... According to Teva, the delivery of loxapine using Alexza's proprietary

Latest news

  • EU approves Alexza’s antipsychotic Adasuve EU approves Alexza’s antipsychotic Adasuve

    Company plans to launch it in third quarter of 2013 in partnership with Grupo Ferrer

  • FDA panel backs Alexza’s inhaled antipsychotic drug

    Shares in Alexza climbed more than 70 per cent after the 9-8 vote by the Psychopharmacologic Drugs Advisory Committee (PDAC) improved the chances that Adasuve (loxapine delivered using Alexza's ... The speed of onset of treatment with inhaled loxapine is

  • Schizophrenia treatments

    The product uses the Alexza's Staccato hand-held, disposable inhaler technology which vaporises loxapine by heating a thin film of the agent. . ... Worldwide revenue projections for inhaled loxapine, cariprazine and TC 5619 are represented in figure

  • Alexza schizophrenia drug delayed

    Alexza said it had completed an end-of-review meeting with the FDA for Adusuve Staccato (loxapine) inhalation aerosol, which is being developed for the rapid treatment of agitation in schizophrenia

  • Alexza psychiatric drug delayed

    Alexza Pharmaceuticals has received a Complete Response Letter (CRL)  from the US Food and Drug Administration (FDA) voicing concerns about the safety of Adusuve Staccato (loxapine) inhalation aerosol.

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics